Repeatability, accuracy, portability, and errors of the portable alignment gyrocompass system

Portable alignment gyrocompass system accuracy, repeatability, portability, and error

Achieving Green and Healthy Homes and Communities in America

In the Fall of 2010, the National Coalition to End Childhood Lead Poisioning contracted with the National Academy to develop and execute an online dialogue that would examine ways to increase the health, safety, and energy efficiency of low- to moderate-income homes. Since 1999, the National Coalition had worked to improve low- to moderate-income housing through the support and execution of home interventions that addressed multiple issues within a home at one time; an approach that often did not align with other traditional, single-issue housing assistance programs. By 2010, the National Coalition had taken on the leadership of the Green and Healthy Homes Initiative, a public-private partnership focused on integrating funding streams to improve low- to middle-income homes across the country.With plans to expand the GHHI's operations, the National Coalition partnered with the National Academy to conduct the National Dialogue on Green and Healthy Homes, a collaborative online dailogue in which participants were asked to identify challenges to, and innovative practices for, improving the health, safety and energy-efficiency of low- to moderate- income homes. The Dialogue was live from November 4-November 22, 2010, and collected 100 hundred ideas and 362 comments from 320 registered users. Over the course of its two and a half week duration, the Dialogue received more than 2,500 visits from over 1,100 people in 48 states and territories. Key FindingsBy reviewing the feedback received in the Dialogue, the Panel was able to make a number of recommendations on how the green and healthy homes community of practice could increase the health, safety and energy efficiency of homes across the country. These recommendations included: Conduct an evaluation of current housing standards to determine if they meet the Nation's health, safety, and energy efficiency needs; Develop a tiered performance standard for healthy, safe and energy efficient homes; Group government funding streams to better align programs with the comprehensive intervention approach; Develop a long-term funding strategy to support efforts after Recovery Act funding ends; and Educate government decisionmakers and the public on the importance of developing green and healthy homes and communities, and the work that supports that development

Talent management in triadic organizational architectures

We study a model of team problem-solving over a large solution space. Compared to the existing literature, we allow for heterogeneity both in the organizational architectures and in the agents' cognitive abilities; moreover, we introduce a more expressive performance measure. We find a robust ranking of the triadic architectures with respect to their effectiveness and provide a key recommendation for talent management in partial hierarchies

Visions: Chaos in Naango

Trailer: https://www.youtube.com/watch?v=kxjqjJNMSFQ Website: http://www.visionsthegame.com Development Blog: http://visionsthegame.tumblr.com Facebook: https://www.facebook.com/visionsthegame/?fref=ts Twitter: https://twitter.com/visionsthegame Email: [email protected]

Patient profiled data for treatment decision-making:valuable as an add-on to hepatitis C clinical guidelines?

Background and Aims: Systematic reviews and medical guidelines are widely used in clinical practice. However, these are often not up-to-date and focussed on the average patient. We therefore aimed to evaluate a guideline add-on, TherapySelector (TS), which is based on monthly updated data of all available high-quality studies, classified in specific patient profiles. Methods: We evaluated the TS for the treatment of hepatitis C (HCV) in an international cohort of patients treated with direct-acting antivirals between 2015 and 2020. The primary outcome was the number of patients receiving one of the two preferred treatment options of the HCV TS, based on the highest level of evidence, cure rate, absence of ribavirin-associated adverse effects, and treatment duration. Results: We enrolled 567 patients. The number of patients treated with one of the two preferred treatment options according to the HCV TS ranged between 27% (2015) and 60% (2020; p &lt; 0.001). Most of the patients received a regimen with a longer treatment-duration (up to 34%) and/or addition of ribavirin (up to 14%). The effect on the expected cure-rate was minimal (1–6% higher) when the first preferred TherapySelector option was given compared to the actual treatment.Conclusions: Medical decision-making can be optimised by a guideline add-on; in HCV its use appears to minimise adverse effects and cost. The use of such an add-on might have a greater impact in diseases with suboptimal cure-rates, high costs or adverse effects, for which treatment options rely on specific patient characteristics.</p

Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus.

Specific differences in signaling and antiviral properties between the different Lambda-interferons, a novel group of interferons composed of IL-28A, IL-28B and IL-29, are currently unknown. This is the first study comparatively investigating the transcriptome and the antiviral properties of the Lambda-interferons IL-28A and IL-29. Expression studies were performed by microarray analysis, quantitative PCR (qPCR), reporter gene assays and immunoluminometric assays. Signaling was analyzed by Western blot. HCV replication was measured in Huh-7 cells expressing subgenomic HCV replicon. All hepatic cell lines investigated as well as primary hepatocytes expressed both IFN-λ receptor subunits IL-10R2 and IFN-λR1. Both, IL-28A and IL-29 activated STAT1 signaling. As revealed by microarray analysis, similar genes were induced by both cytokines in Huh-7 cells (IL-28A: 117 genes; IL-29: 111 genes), many of them playing a role in antiviral immunity. However, only IL-28A was able to significantly down-regulate gene expression (n = 272 down-regulated genes). Both cytokines significantly decreased HCV replication in Huh-7 cells. In comparison to liver biopsies of patients with non-viral liver disease, liver biopsies of patients with HCV showed significantly increased mRNA expression of IL-28A and IL-29. Moreover, IL-28A serum protein levels were elevated in HCV patients. In a murine model of viral hepatitis, IL-28 expression was significantly increased. IL-28A and IL-29 are up-regulated in HCV patients and are similarly effective in inducing antiviral genes and inhibiting HCV replication. In contrast to IL-29, IL-28A is a potent gene repressor. Both IFN-λs may have therapeutic potential in the treatment of chronic HCV